Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

Clinical trial NCT06663059 · RECRUITING

Trial details

NCT number: NCT06663059
Sponsor: Tang-Du Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Cancer

Start date: 2024-10-01
Primary completion: 2025-12-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.